Skip to main content

Advertisement

SpringerLink
Log in

Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

The prognosis of patients with WHO grade III gliomas is highly dependent on their genomic status such as the isocitrate dehydrogenase (IDH) 1/2 mutation and1p/19q co-deletion. However, difficulties have been associated with determining which tumors have certain genomic profiles by preoperative radiographical modalities, and the role of surgical resection in achieving better outcomes remains unclear. This retrospective study included 124 consecutive patients with newly diagnosed grade III gliomas. The genomic status of IDH1/2 and 1p/19q was analyzed in these patients. Tumors were then divided into 3 subgroups based on their genomic status; the IDH 1/2 mutation with the 1p/19q co-deletion (1p/19q co-del), the IDH 1/2 mutation without the 1p/19q co-deletion (non-1p/19q co-del), and the IDH 1/2 wild type (IDH wt). Survival times were compared between patients who underwent gross total resection and those who did not (GTR versus non-GTR). The relationships between genomic statuses and MR imaging characteristics such as ring-like or nodular enhancements by gadolinium, and very low intensity on T1-weighted images with blurry enhancements (T1VL) were also examined. Among all patients with grade III gliomas, GTR patients had longer median survival and progression-free times than those of non-GTR patients (undefined versus 87 months, p = 0.097, and 124 versus 34 months, p = 0.059, respectively). No significant differences were observed in survival between GTR and non-GTR patients in the 1p/19q co-del group (p = 0.14), or between GTR and non-GTR patients in the IDH wt group (26 and 27 months, p = 0.29). On the other hand, in non-1p/19q co-del group, survival was significantly longer in GTR patients than in non-GTR patients (undefined versus 77 months, p = 0.005). Radiographically, T1VL was detected in most tumors in the non-1p/19q co-del group (78.2 %), but only 6 (21.4 %) and 17 (41.5 %) tumors in the 1p/19q co-del and IDH wt groups, respectively. A correlation was not found between other genomic subgroups and MR imaging findings. Strict surgical removal is important to improve the prognosis of patients with grade III gliomas, especially for tumors with the IDH 1/2 mutation without the 1p/19q co-deletion. The MR finding of T1VL can be used to select candidates for more radical resection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Abbreviations

CT:

Computed tomography

FLAIR:

Fluid-attenuated inversion recovery

GTR:

Gross total resection

IDH:

Isocitrate dehydrogenase

MGMT:

O6-methylguanine-methyltransferase

MR:

Magnetic resonance

OS:

Overall survival

PFS:

Progression-free survival

WHO:

World Health Organization

References

  1. Louis ND, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007) WHO classification of tumours of the central nervous system. IARC Press, Lyon

    Google Scholar 

  2. Balss J, Meyer J, Mueller W Korsthunov A, Hartmann C, von Deimling A (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116(6):597–602

    Article  CAS  PubMed  Google Scholar 

  3. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337–343

    Article  CAS  PubMed  Google Scholar 

  4. Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, Colins VP (2009) IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol 11(4):341–347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64(6):479–489

    Article  CAS  PubMed  Google Scholar 

  6. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Shibahara I, Sonoda Y, Kanamori M, Saito R, Yamashita Y, Kumabe T, Watanabe M, Suzuki H, Kato S, Ishioka C, Tominaga T (2012) IDH1/2 gene status defines the prognosis and molecular profiles in patients with grade III gliomas. Int J Clin Oncol 17(6):551–561

    Article  CAS  PubMed  Google Scholar 

  8. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y Suzuki H, Tominaga T (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Sci 100:1996–1998

    Article  CAS  PubMed  Google Scholar 

  9. Sonoda Y, Yokosawa M, Saito R, Kanamori M, Yamashita Y, Kumabe T, Watanabe M, Tominaga T (2010) O(6)-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma. Int J Clin Oncol 15(4):352–358

    Article  CAS  PubMed  Google Scholar 

  10. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ et al (2006) Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European organisation for research and treatment of cancer phase III trial. J Clin Oncol 24(18):2715–2722

    Article  PubMed  Google Scholar 

  11. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P et al (2010) IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res 16(5):1597–1604

    Article  PubMed  Google Scholar 

  12. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360(8):765–773

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Sonoda Y, Kumabe T, Watanabe M, Nakazato Y, Inoue T, Kanamori M, Tominaga T (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. Acta Neurochir (Wien) 151(11):1349–1358

    Article  Google Scholar 

  14. Sonoda Y, Tominaga T (2010) 2-hydroxyglutarate accumulation caused by IDH mutation is involved in the formation of malignant gliomas. Expert Rev Neurother 10(4):487–489

    Article  CAS  PubMed  Google Scholar 

  15. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: intergroup radiation therapy oncology group trial 9402. J Clin Oncol 24(18):2707–2714

    Article  CAS  PubMed  Google Scholar 

  16. Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J, Benouaich-Amiel A et al (2006) Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer 107(8):1891–1897

    Article  CAS  PubMed  Google Scholar 

  17. Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K et al (2012) Significance of IDH mutations varies with tumor histology, grade and genetics in Japanese glioma patients. Cancer Sci 103(3):587–592

    Article  CAS  PubMed  Google Scholar 

  18. Wick W, Hartmann C, Engel C, Stoffeles M, Felsberg J, Stockhammer F et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27(35):5874–5880

    Article  CAS  PubMed  Google Scholar 

  19. Keles GE, Anderson B, Berger MS (1999) The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. Surg Neurol 52(4):371–379

    Article  CAS  PubMed  Google Scholar 

  20. McGirt MJ, Mukherjee D, Chaichana KL, Than KD, Weingart JD, Quinones-Hinojosa A (2009) Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. Neurosurgery 65(3):463–470

    Article  PubMed  Google Scholar 

  21. Kawaguchi T, Saito R, Kanamori M, Yamashita Y, Sonoda Y Tominaga T (2013) Clinical significance and limitations of repeat resection for pediatric malignant neuroepithelial tumors: clinical article. J Neurosurg Pediatr 12(4):309–316

    Article  PubMed  Google Scholar 

  22. Nomiya T, Nemoto K, Kumabe T, Takai Y, Yamada S (2007) Prognostic significance of surgery and radiation therapy in cases of anaplastic astrocytoma: retrospective analysis of 170 cases. J Neurosurg 106(4):575–581

    Article  PubMed  Google Scholar 

  23. Mashiyama S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K (1991) Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 6(8):1313–1318

    CAS  PubMed  Google Scholar 

  24. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P (2006) Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn 8(4):433–443

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-Sprenger S, McLendon R, Wesseling P (2009) Robust detection of EGFR copy number changes and EGFR variant III: technical aspects and relevance for glioma diagnostics. Brain Pathol 19(4):661–671

    Article  PubMed  PubMed Central  Google Scholar 

  26. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A, Sijben A, Boots-Sprenger S, Wesseling P (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest 87(10):1055–1065

    Article  CAS  PubMed  Google Scholar 

  27. Louis ND, Perry A, Burger P, Ellison WD, Reifenberger G, von Deimling A et al (2014) International society of neuropathology-haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 24(5):429–435

    Article  PubMed  Google Scholar 

  28. Reyes-Botero G, Dehais C, Idbaih A, Martin-Duverneuil N, Lahutte M, Carpentier C et al (2014) Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression. Neuro Oncol 16(5):662–670

    Article  CAS  PubMed  Google Scholar 

  29. Sonoda Y, Shibahara I, Kawaguchi T, Saito R, Kanamori M, Watanabe M, Suzuki H, Kumabe T, Tominaga T (2015) Association between molecular alterations and tumor location and MRI characteristics in anaplastic gliomas. Brain Tumor Pathol 32(2):99–104

    Article  CAS  PubMed  Google Scholar 

  30. Kawaguchi T, Kumabe T, Saito R, Kanamori M, Iwasaki M, Yamashita Y, Sonoda Y, Tominaga T (2014) Practical surgical indicators to identify candidates for radical resection of insulo-opercular gliomas. J Neurosurg 121(5):1124–1132

    Article  PubMed  Google Scholar 

  31. Turkalp Z, Karamchandani J, Das S (2014) IDH mutation in glioma: new insights and promises for the future. JAMA Neurol 71(10):1319–1325

    Article  PubMed  Google Scholar 

  32. Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS (2006) Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg 105(1):34–40

    Article  PubMed  Google Scholar 

  33. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M et al (2014) IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro Oncol 16(1):81–91

    Article  CAS  PubMed  Google Scholar 

  34. Cordier D, Gozé C, Schädelin S, Rigau V, Mariani L, Duffau H (2015) A better surgical resectability of WHO grade II gliomas is independent of favorable molecular markers. J Neurooncol 121(1):185–193

    Article  CAS  PubMed  Google Scholar 

  35. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker FN II (2005) Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11:8600–8605

    Article  CAS  PubMed  Google Scholar 

  36. Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR (2010) An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 49(2):1398–1405

    Article  CAS  PubMed  Google Scholar 

  37. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891

    Article  PubMed  Google Scholar 

  38. Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10(13):4303–4306

    Article  PubMed  Google Scholar 

  39. Qi S, Yu L, Li H, Ou Y, Qiu X, Ding Y, Han H, Zhang X (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7(6):1895–1902

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29(34):4482–4490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372(26):2499–2508

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ellison DW. (2015) Multiple molecular data sets and the classification of adult diffuse gliomas. N Engl J Med 372(26):2555–2557

    Article  CAS  PubMed  Google Scholar 

  43. Andronesi OC, Rapalino O, Gerstner E, Chi A, Batchelor TT, Cahill DP, Sorensen AG, Rosen BR (2013) Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. Clin Invest 123(9):3659–3663

    Article  CAS  Google Scholar 

  44. Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y et al (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47(5):458–468

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

    Tomohiro Kawaguchi, Ichiyo Shibahara, Ryuta Saito, Masayuki Kanamori & Teiji Tominaga

  2. Department of Neurosurgery, Faculty of Medicine, Yamagata University School of Medicine, 2-2-2 Iidanishi, Yamagata, Yamagata, 990-9585, Japan

    Yukihiko Sonoda

  3. Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan

    Toshihiro Kumabe

Authors
  1. Tomohiro Kawaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yukihiko Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ichiyo Shibahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ryuta Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masayuki Kanamori
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toshihiro Kumabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Teiji Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yukihiko Sonoda.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kawaguchi, T., Sonoda, Y., Shibahara, I. et al. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. J Neurooncol 129, 505–514 (2016). https://doi.org/10.1007/s11060-016-2201-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-016-2201-2

Keywords

Search

Navigation